Introduction: Solving the Zoonotic Parasite Transmission and Pet Health Threat For veterinarians and pet owners, internal parasites (helminths) infecting dogs and cats – roundworms (Toxocara canis, Toxocara cati), hookworms (Ancylostoma caninum, Ancylostoma tubaeforme, Uncinaria stenocephala), tapeworms (Dipylidium caninum, Taenia spp., Echinococcus spp.), whipworms (Trichuris vulpis), heartworms (Dirofilaria immitis), and lungworms (Aelurostrongylus abstrusus) – cause gastrointestinal disease (diarrhea, vomiting, weight loss, poor coat, potbelly appearance, anemia, intussusception, intestinal obstruction, failure to thrive), zoonotic transmission (visceral larva migrans (VLM), ocular larva migrans (OLM) from roundworm eggs, cutaneous larva migrans (CLM) from hookworm larvae), and can be fatal in young puppies/kittens. Dog and cat dewormers (anthelmintics) are pharmaceutical compounds (pyrantel pamoate, praziquantel, fenbendazole, milbemycin oxime, ivermectin, selamectin, moxidectin, epsiprantel, oxantel, febantel, nitroscanate, flubendazole) that paralyze, kill, or expel worms. According to the latest industry report released by Global Leading Market Research Publisher QYResearch, "Dog and Cat Dewormer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032", the global market for Dog and Cat Dewormer was estimated to be worth US millionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. Dog and cat dewormers are medications specifically designed to eliminate internal parasites, or worms, that can infest the digestive tract of dogs and cats. Internal parasites such as roundworms, hookworms, tapeworms, and whipworms can be harmful to pets' health if left untreated. Deworming is an essential part of pet care to maintain their well-being and prevent the spread of parasites. There are different types of dewormers available for dogs and cats, and they come in various forms, including tablets, liquids, and topical treatments. These dewormers work to target specific types of parasites and remove them from the animal's system. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5974267/dog-and-cat-dewormer 1. Formulation Type Deep Dive: Topical vs. Oral Dewormers Unlike injectable anthelmintics, dog and cat dewormers segment by route of administration: Topical Dewormers (40% market share): Spot-on, transdermal liquid applied to skin (base of neck, between shoulder blades). Absorbed systemically (heartworm prevention, intestinal nematodes). Contains selamectin, moxidectin, fipronil (combination). Convenient for pet owners (easy application, no pill struggle). Growing 8% CAGR. Oral Dewormers (60% share, largest): Tablets, chewable, liquid suspension, paste, granules, powder. Pyrantel pamoate, praziquantel, fenbendazole, milbemycin oxime, ivermectin. Palatable formulations (beef flavor, liver flavor, chicken flavor, pork flavor, cheese flavor, tuna flavor). Growing 6% CAGR. Industry Insight (2026 Data) : Topical dewormers fastest-growing (8% CAGR), driven by convenience, compliance (owner easier than pilling), and combo products (flea + tick + heartworm + intestinal worm). 2. Application Deep Dive: Dogs vs. Cats vs. Others Dogs (65% market share, largest): Roundworms, hookworms, whipworms, tapeworms, heartworms. A case study from Zoetis (December 2025) – Simparica Trio (oral chewable) for dogs (sarolaner + moxidectin + pyrantel). Canine segment growing 6% CAGR. Cats (35% share, fastest-growing +9% CAGR): Roundworms, hookworms, tapeworms. A case study from Boehringer Ingelheim (January 2026) – Profender (topical, emodepside + praziquantel) for cats, combination wormer. Cat segment growing 9% CAGR (pet humanization, indoor/outdoor). 3. Competitive Landscape & Regional Developments (Last 6 Months) Zoetis (Pfizer) (US, 25% market share): Simparica (dogs), Revolution (topical). December 2025 – "Simparica Trio". Supplies US, EU, global. Boehringer Ingelheim (Germany, 20% share): Heartgard (ivermectin), Panacur (fenbendazole). October 2025 – "NexGard Spectra". Supplies global. Merck (US, 15% share): Bravecto (fluralaner). Elanco (US, 10% share). Bayer (Germany, 8% share). PetIQ (US, 5% approx) OTC dewormers (retail). Technology Bottleneck: Primary challenge is drug resistance (anthelmintic resistance in roundworms, hookworms, whipworms). Over past 6 months, Zoetis filed patent for combination product (multiple MOA). Boehringer introduced "Panacur" (broad spectrum). 4. Policy Drivers and Forecast (2026-2032) Pet Humanization (Dog and cat ownership) : 470M pet dogs (global), 370M pet cats (global). Routine deworming (every 3 months). Zoonotic Disease Prevention (Roundworm, Hookworm) : CDC, WHO recommend deworming pets to protect children (visceral larva migrans, ocular larva migrans). Heartworm Prevention (mosquito-borne) : Monthly preventative (ivermectin, milbemycin, moxidectin). Prescription required. Market growth projections 7-9% CAGR (2026-2032). Topical fastest-growing (8% CAGR). Dogs largest segment (65% share). North America largest region (45% share). 5. Original Analysis: The Prescription vs. OTC Dewormer and Broad Spectrum My exclusive analysis reveals prescription dewormers (heartworm prevention, milbemycin, moxidectin, selamectin) require veterinarian authorization. OTC dewormers (pyrantel pamoate, praziquantel) available over-the-counter (retail, e-commerce) but less broad-spectrum. Furthermore, I observe combination products (flea + tick + heartworm + intestinal worm) for convenience (Simparica Trio, NexGard Spectra, Revolution Plus). Trending. A counter-intuitive finding: Puppies and kittens deworming every 2 weeks (2,4,6,8 weeks) for roundworms, hookworms (vertical transmission from mother). Dewormer manufacturer recommendation. Finally, I predict that by 2028, broad-spectrum dewormers (tablet, topical) with resistance-breaking technology (new chemical class). Zoetis, Boehringer, Merck. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp